Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
Moderna’s stock surged around 20% following its Science Day event, with trading pressure tied partly to high short interest. But the company’s longer-term push for mRNA medicines beyond vaccines still faces a multi-year ramp before revenue from key parts of its pipeline may arrive.
THE APEX TIMES
THE APEX TIMES
A Yahoo Finance report tied Eli Lilly’s stock strength to growing inclusion of GLP-1 therapies in Medicare-related coverage, highlighting how policy access can reshape demand for weight-loss and diabetes treatments.
THE APEX TIMES
The insurer says Guardant Health’s Shield blood test for colorectal cancer screening is now covered for eligible patients, highlighting how payers are moving beyond colonoscopy-only approaches for some screenings.
THE APEX TIMES
A regulatory update in Europe involving Johnson & Johnson’s Tecvayli in combination with Darzalex SC adds to the company’s cancer pipeline progress, while the latest market chatter around a talc verdict focuses on easing one legal overhang.
THE APEX TIMES
UnitedHealth said it will begin offering insurance coverage for Guardant Health’s colorectal cancer test effective August 1, a move investors appear to be linking to renewed demand for the diagnostic and to broader payer adoption of liquid biopsy screening.
THE APEX TIMES
A market-news analysis argues that Eli Lilly’s growth outlook supports a double-digit upside case for its stock, projecting a 12.5% gain from a recent trading reference point.
THE APEX TIMES
A fresh Yahoo Finance preview argues CVS Health’s history of earnings surprises and the current setup heading into its next quarterly report could point to another beat.
THE APEX TIMES
The hospital operator says new research published in the New England Journal of Medicine offers encouraging early findings for a gene-editing approach, without providing additional clinical details in its announcement.
THE APEX TIMES
A market commentary framed Pfizer and Verizon Communications as two “high-yield” dividend plays, positioning both as established companies with fundamentals the author views as supportive. The available text does not include the underlying dividend or valuation figures that would normally be central to the debate.
